



BioInvent is granted a patent in Europe for the immune-oncology antibody BI-505

Lund, Sweden – 16 March 2016 – BioInvent International (BINV) announces today that the European Patent Office, EPO, has decided to grant the company's patent EP 1 960 432, relating to the immune-oncology antibody BI-505. BioInvent plans to shortly initiate a Phase II trial with BI-505 in patients with multiple myeloma, with the aim to prevent or significantly delay relapse of this serious form of hematologic cancer.

The European patent for BI-505 will enter into force on 6 April 2016 and will expire in 2026. Corresponding patents have already been granted in the US, Japan, Australia, China, South Korea and Russia, among other countries.

"The extended geographical patent protection for BI-505 increases the value of our project and underlines BioInvent's ability to develop innovative and unique antibodies against severe cancer diseases", **says Michael Oredsson, CEO of BioInvent.**

During 2016, the start of clinical studies for three of BioInvent's clinical phase drug projects are planned. In addition to the study mentioned above with BI-505, clinical studies are also expected to be initiated with BI-1206 in patients with non-Hodgkin lymphoma and chronic lymphatic leukaemia, and with TB-403 for treatment of rare but serious types of cancer in children.

To the editors:

About BioInvent

BioInvent International AB develops immune oncology drugs. With one of the world's largest antibody libraries, and a unique, proprietary discovery method, BioInvent can identify the optimal cellular targets and antibodies for the treatment of various tumor types. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. This makes it possible to develop proprietary drug projects, but also to supply leading international pharmaceutical companies with effective tools for their drug development. BioInvent currently has three proprietary projects in or close to clinical development and partnership agreements with seven global pharmaceutical and biotech companies. More information is available at www.bioinvent.com.

About BI-505

BI-505 is a human antibody against ICAM-1 developed by BioInvent, which will be clinically tested in cooperation with researchers at Penn Medicine as an immuno-oncological therapy to prevent or delay relapse in patients with multiple myeloma (a form of bone marrow cancer) undergoing stem-cell transplantation. Preclinical data indicates improved activity against myeloma when BI-505 is administered in combination with Velcade® or Revlimid®. BI-505's favourable safety profile has been demonstrated in a previous phase I trial. This and the unique mechanism of action, "flagging" remaining myeloma cells for elimination by actively recruited macrophages, as well as the potential to inhibit ICAM-1 dependent survival signals between myeloma cells and tumour stroma, indicate a unique possibility of improving the therapeutic effect of stem-cell transplantation.

For further information, please contact:

Michael Oredsson

President and CEO

+46 (0)46 286 85 67

+46 (0)70716 89 30

michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No: 556537-7263

Visiting address: Sölvegatan 41

Mailing address: 223 70 LUND

Phone: +46(0)46 286 85 50

info@bioinvent.com

www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 16 March, 2016.